Dermatology Drugs Market Size to Surpass USD 51.71 BN by 2032
The dermatology drugs market size was estimated at USD 17.35 billion in 2022 and is expected to surpass around USD 51.71 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 11.54% during the forecast period 2023 to 2032.
Key Takeaways:
Dermatology Drugs Market Report Scope
| Report Attribute | Details |
| Market Size in 2023 | USD 19.35 Billion |
| Market Size by 2032 | USD 51.71 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 11.54% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Indication, Distribution Channel Administration Analysis |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | LUPIN (India), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Amgen inc. (U.S.), Lilly (U.S.), AstraZeneca (U.K.), AbbVie Inc (U.S.), Johnson & Johnson Private Limited (U.S.), LEO Pharma A/S (Denmark), Merck & Co., Inc (U.S.), Bausch Health Companies Inc (Canada), Bristol-Myers Squibb Company (U.S.). |
The market for dermatological medications is expanding as a result of the rise in patients with dermatitis, fungal, and acne. According to data from the American Association of Dermatologists, acne affects almost 50 million individuals in the US alone. Skin and other associated issues can arise for a variety of causes, including improper body care, excessive perspiration, consuming hot foods, and wearing constricting clothing. As a result, the market is observing a rise in the sales of medications used for treatments. It has been demonstrated that increased public knowledge of skin and hair infections presents a potential opportunity for the industry. The sale of over-the-counter (OTC) medications, which are frequently used to treat hair loss and acne, has increased as a result of increased knowledge. Due to hormonal fluctuations, most young people and teenagers have skin-related problems such as skin irritability, acne, and excessive perspiration. The market is anticipated to continue expanding because of the increase in demand for dermatological medications that are regularly used as anti-inflammatory agents and cleansers topically. Other considerations include an increase in spending on R&D by industry leaders for the creation and clinical testing of new medications as a result of the rise in demand for innovative, efficient, and affordable medications. The rise in skin cancer cases and other illnesses is contributing to the expansion of the pharmaceutical industry. However, a number of adverse effects and inappropriate application of dermatological medications, together with governmental limitations and guidelines, will prevent the industry from developing to its full potential.
Indication Insights
The psoriasis segment dominated the market with a revenue share of more than 36.16% in 2022 and is expected to expand with the highest CAGR of 11.6% from 2023 to 2032. Psoriasis is caused by the immune system mistakenly attacking healthy skin cells. Psoriasis is not a contagious disease. The disease causes swollen fingers and toes, foot pain, lower back pain, nail changes, and eye inflammation. Psoriasis can be triggered by stress, skin injury, infections, some drugs, and heavy drinking. Psoriasis is found in all age groups but is majorly seen in adults and contributes to the global dermatology drug revenue.
The alopecia segment is likely to expand with the second-highest CAGR of 10.9% from 2023 to 2032. Alopecia caused due to the body’s immune system attacking hair follicles resulting in hair loss. Alopecia is an autoimmune disorder that results in hair coming out. Both men and women suffer from Alopecia due to an imbalance of hormones, hair care treatments, scalp infections, and possible side effects of some medications. Additionally, hereditary hair loss is the most common cause of hair loss globally. Citizens are careful about hair loss and visit hospitals for diagnosis. Hair loss requires ongoing treatments for a long period and contributes to the market growth rate.
Distribution Channel Insights
Due to a growth in patient visits and sales of prescription-only medications for the treatment of dermatological skin problems, the hospital pharmacy segment commands the greatest proportion of the worldwide dermatology drug market. This segment is expanding as a result of an increase in patient preference for local pharmacies and the accessibility of inexpensive OTC products. Due to the widespread use of online portals and websites like Amazon and Walmart, the online pharmacy market is anticipated to grow at a profitable CAGR over the course of the projected period.
Administration Analysis Insights
In 2022, the parenteral administration market sector held a monopoly. The introduction of biologics for the treatment of dermatological disorders is responsible for the segment's dominance. Furthermore, it is anticipated that a growth in patient desire for tropical remedies would drive up sales of the items. Due to the US FDA's clearance of oral medicines, the oral category is predicted to have a substantial CAGR throughout the projection period.
Regional Insights
The North America region accounted for 39.80% of the revenue share in 2022. Due to the greater prevalence of skin conditions and diseases in the continent, North America accounted for the bulk of the market. According to statistics from statistica.com, in the US, those between the ages of 18 and 29 made the largest proportion of dermatologist visits, at 16.9%, followed by those between 50 and 64 at 15.78%, and those between 30 and 49 at 12.95%. Additionally, the introduction of new medications and the existence of significant industry-important players are fueling market expansion. The primary market growth contributors in the area are the USA, Canada, and Mexico. Because big businesses make significant investments in research and development for the creation of new pharmaceuticals, the European area ranks second on the market. The market is being driven by an increase in the prevalence of skin diseases among individuals and a decrease in the number of visits people are making for treatment. The fourth most prevalent sickness among people is a skin problem or disease, which has led to an increase in medicine demand throughout time. Due to the greater number of young patients, France, Germany, and Italy are the main contributors to the market growth in the area. Due to the relocation of important regional companies and growing awareness, the Middle East and Africa market is also exhibiting growth rates.
Because of the area's increased awareness of skin diseases and access to effective skin treatments, the Asia-Pacific region is anticipated to have the largest market growth. The market expansion has been encouraged by the availability of appropriate healthcare facilities. The annual Asia-Pacific Dermatology conference, which is held in several countries, is the main driver of market expansion in this area. where countries in the Asia-Pacific region congregate to talk about advancement, cooperation, concepts for better patient care, and medication development in the area. The three countries with the largest market shares in the area are China, Japan, and India.
Recent Developments
Some of the prominent players in the Dermatology Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Dermatology Drugs market.
By Indication
By Distribution Channel
By Administration Analysis
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatology Drugs Market
5.1. COVID-19 Landscape: Dermatology Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermatology Drugs Market, By Indication
8.1. Dermatology Drugs Market, by Indication, 2023-2032
8.1.1 Acne
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Psoriasis
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Rosacea
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Alopecia
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Dermatology Drugs Market, By Distribution Channel
9.1. Dermatology Drugs Market, by Distribution Channel, 2023-2032
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Online Pharmacies
Chapter 10. Global Dermatology Drugs Market, By Administration Analysis
10.1. Dermatology Drugs Market, by Administration Analysis, 2023-2032
10.1.1. Topical Administration
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Oral Administration
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Parenteral Administration
Chapter 11. Global Dermatology Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2020-2032)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2020-2032)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2020-2032)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2020-2032)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2020-2032)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Administration Analysis (2020-2032)
Chapter 12. Company Profiles
12.1. LUPIN (India)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG (Switzerland)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd (Switzerland)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc. (U.S.)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sanofi (France)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen inc. (U.S.)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Lilly (U.S.)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AstraZeneca (U.K.)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AbbVie Inc (U.S.)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson & Johnson Private Limited (U.S.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers